Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

486 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort.
Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, Ruppin E, Magen E, Vinker S. Israel A, et al. medRxiv [Preprint]. 2021 Aug 5:2021.08.03.21261496. doi: 10.1101/2021.08.03.21261496. medRxiv. 2021. PMID: 34401882 Free PMC article. Updated. Preprint.
IMPORTANCE: Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated its population, achieving early control over the spread of the virus. ...OBJECTIVE: To determine whether time elapsed since the second BNT1 …
IMPORTANCE: Israel was among the first countries to launch a large-scale COVID-19 vaccination campaign, and quickly vaccinated …
Increased microRNA activity in human cancers.
Israel A, Sharan R, Ruppin E, Galun E. Israel A, et al. PLoS One. 2009 Jun 25;4(6):e6045. doi: 10.1371/journal.pone.0006045. PLoS One. 2009. PMID: 19557174 Free PMC article.
Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population.
Israel A, Schäffer AA, Cicurel A, Feldhamer I, Tal A, Cheng K, Sinha S, Schiff E, Lavie G, Ruppin E. Israel A, et al. medRxiv [Preprint]. 2021 Mar 24:2020.10.13.20211953. doi: 10.1101/2020.10.13.20211953. medRxiv. 2021. PMID: 33083810 Free PMC article. Updated. Preprint.
BACKGROUND: Until COVID-19 drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Towards this objective, we conducted a large population s …
BACKGROUND: Until COVID-19 drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether e …
Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population.
Israel A, Schäffer AA, Cicurel A, Cheng K, Sinha S, Schiff E, Feldhamer I, Tal A, Lavie G, Ruppin E. Israel A, et al. Elife. 2021 Jul 27;10:e68165. doi: 10.7554/eLife.68165. Elife. 2021. PMID: 34313216 Free PMC article.
BACKGROUND: Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted …
BACKGROUND: Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is cr …
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study.
Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, Ruppin E, Magen E, Vinker S. Israel A, et al. BMJ. 2021 Nov 24;375:e067873. doi: 10.1136/bmj-2021-067873. BMJ. 2021. PMID: 34819275 Free PMC article.
DESIGN: Test negative design study. SETTING: Electronic health records of a large state mandated healthcare organisation, Israel. PARTICIPANTS: Adults aged 18 years who had received a reverse transcription polymerase chain reaction (RT-PCR) test between 15 Ma …
DESIGN: Test negative design study. SETTING: Electronic health records of a large state mandated healthcare organisation, Israel …
Predicting COVID-19 severity using major risk factors and received vaccines.
Israel A, Schäffer AA, Merzon E, Green I, Magen E, Golan-Cohen A, Vinker S, Ruppin E. Israel A, et al. medRxiv [Preprint]. 2022 Jan 3:2021.12.31.21268575. doi: 10.1101/2021.12.31.21268575. medRxiv. 2022. PMID: 35018390 Free PMC article. Updated. Preprint.
METHODS: Electronic health records from 101,039 individuals infected with SARS-CoV-2, since the beginning of the pandemic and until November 30, 2021 were extracted from a national healthcare organization in Israel. Logistic regression models were built to estimate …
METHODS: Electronic health records from 101,039 individuals infected with SARS-CoV-2, since the beginning of the pandemic and until November …
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection.
Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Israel A, et al. Vaccines (Basel). 2021 Dec 31;10(1):64. doi: 10.3390/vaccines10010064. Vaccines (Basel). 2021. PMID: 35062724 Free PMC article.
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospective study, conducted at Leumit Health Services in Israel, to determine the kinetics of SARS-CoV-2 IgG antibodies following administr …
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospec …
486 results